Evidence map›Paper›PMID 27354525›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance.

Benedetta Bigio, Aleksander A Mathé, Vasco C Sousa, Danielle Zelli, Per Svenningsson, Bruce S McEwen, Carla Nasca

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Acetyl-l-carnitine deficiency in patients with major depressive disorder.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Venlafaxine's effect on resilience to stress is associated with a shift in the balance between glucose and fatty acid utilization.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Carnitine and Depression.Frontiers in nutrition · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Benedetta BigioCenter for Clinical and Translational Science, The Rockefeller University, New York, NY 10065; Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065; bbigio@rockefeller.edu mcewen@rockefeller.edu cnasca@rockefeller.edu.
Aleksander A MathéDepartment of Clinical Neuroscience, Karolinska Institutet, 171 77 Solna, Stockholm, Sweden.
Vasco C SousaDepartment of Clinical Neuroscience, Karolinska Institutet, 171 77 Solna, Stockholm, Sweden.
Danielle ZelliLaboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065;
Per SvenningssonDepartment of Clinical Neuroscience, Karolinska Institutet, 171 77 Solna, Stockholm, Sweden.
Bruce S McEwenLaboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065; bbigio@rockefeller.edu mcewen@rockefeller.edu cnasca@rockefeller.edu.
Carla NascaLaboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065; bbigio@rockefeller.edu mcewen@rockefeller.edu cnasca@rockefeller.edu.
Rockefeller University · USKarolinska Institutet · SE

Funding

Transforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8M
NCATS NIH HHS UL1 TR000043
6 · The paper itself

Abstract

Although regulation of energy metabolism has been linked with multiple disorders, its role in depression and responsiveness to antidepressants is less known. We found that an epigenetic and energetic agent, acetyl-l-carnitine (LAC, oral administration), rapidly rescued the depressive- and central and systemic metabolic-like phenotype of LAC-deficient Flinders Sensitive Line rats (FSL). After acute stress during LAC treatment, a subset of FSL continued to respond to LAC (rFSL), whereas the other subset did not (nrFSL). RNA sequencing of the ventral dentate gyrus, a mood-regulatory region, identified metabolic factors as key markers predisposing to depression (insulin receptors Insr, glucose transporters Glut-4 and Glut-12, and the regulator of appetite Cartpt) and to LAC responsiveness (leptin receptors Lepr, metabotropic glutamate receptors-2 mGlu2, neuropeptide-Y NPY, and mineralocorticoid receptors MR). Furthermore, we found that stress-induced treatment resistance in nrFSL shows a new gene profile, including the metabolic regulator factors elongation of long chain fatty acids 7 (Elovl7) and cytochrome B5 reductase 2 (Cyb5r2) and the synaptic regulator NPAS4. Finally, while improving central energy regulation and exerting rapid antidepressant-like effects, LAC corrected a systemic hyperinsulinemia and hyperglicemia in rFSL and failed to do that in nrFSL. These findings establish CNS energy regulation as a factor to be considered for the development of better therapeutics. Agents such as LAC that regulate metabolic factors and reduce glutamate overflow could rapidly ameliorate depression and could also be considered for treatment of insulin resistance in depressed subjects. The approach here serves as a model for identifying markers and underlying mechanisms of predisposition to diseases and treatment responsiveness that may be useful in translation to human behavior and psychopathology.

Indexed as

AcetylcarnitineAnimalsAntidepressive AgentsDentate GyrusDepressionDisease Models, AnimalDrug ResistanceEnergy MetabolismEpigenesis, GeneticGene Expression ProfilingHyperglycemiaHyperinsulinismMaleRatsStress, PsychologicalAcetylcarnitineAntidepressive Agentsacetylcarnitinedentate gyrusinsulinmetabolic factorsRNAseq

Identifiers

PMID27354525
PMCPMC4948346
OpenAlexW2475256373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.